BioNexus Gene Lab Corp. (BGLC) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.19

From 52W high−77.59%

Volume2271.00

Market cap$3.60M

P/E (TTM)—

P/S (TTM)1.2x

Div yield—

Key dataOct 19, 2026

Open

$1.19

From 52W high

−77.59%

Volume

2271.00

Market cap

$3.60M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

42.0

MomentumView details →

1D Return

+1.48%

YTD Return

−68.86%

SummaryUpdated Jun 1, 2026

BioNexus Gene Lab Corp. (NASDAQ:BGLC) is a Malaysian-based company incorporated in 2017 and headquartered in Kuala Lumpur. The company went public on January 8, 2021, and operates through two primary subsidiaries across Southeast Asia. Originally focused on chemical raw materials distribution, BioNexus has been expanding into the medical diagnostics sector, positioning itself as a dual-business entity serving both industrial and healthcare markets in Malaysia, Indonesia, Vietnam, and other Southeast Asian countries.

Ask drillr about BioNexus Gene Lab Corp. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

0.1x

P/S (TTM)

1.2x

P/B (TTM)

0.5x

ProfitabilityView details →

Gross Margin

11.64%

Net Margin

−82.36%

EBITDA Margin

−76.50%

ROE (TTM)

−33.11%

ROA (TTM)

−29.51%

Asset Turnover

0.21x

GrowthView details →

Revenue YoY

−67.27%

EPS YoY

+22.70%

FCF YoY

—

Revenue CAGR 3Y

−12.09%

EPS CAGR 3Y

−78.89%

EBITDA YoY

+13.90%

MomentumView details →

1D Return

+1.48%

YTD Return

−68.86%

1Y Return

−76.30%

RSI (14)

42.0

vs 50D SMA

−14.15%

vs 200D SMA

−41.05%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

6.08x

Quick Ratio

5.28x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.12

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

3.13M

Net Income (TTM)

−2.58M

Op. CF (TTM)

−842373.00

Latest newsMore news →

RYET entered an exclusive license agreement with BioNexus Gene Lab to bring Cogni AI into Malaysian healthcare, granting RYET a 10% royalty on qualifying technology receipts and 560,000 BGLC shares in a reciprocal share exchange.14d ago

Similar companies

Aspira Women's Health Inc.AWH bioAffinity Technologies, Inc.BIAF Inotiv, Inc.NOTV Intelligent Bio Solutions Inc.INBS iSpecimen Inc.ISPC Trinity Biotech plcTRIB Find similar companies →

Latest newsMore news →

BioNexus Gene Lab Corp signed an agreement with Ruanyun Edai Technology Inc. for an exclusive ten-year Malaysian healthcare licence to the CogniAI platform, with two five-year renewal options, in exchange for 410,000 BioNexus shares valued at US$3.5 million and a 10% royalty on defined technology receipts.12d ago RYET entered an exclusive license agreement with BioNexus Gene Lab to bring Cogni AI into Malaysian healthcare, granting RYET a 10% royalty on qualifying technology receipts and 560,000 BGLC shares in a reciprocal share exchange.14d ago BioNexus Gene Lab Corp. announced progress toward commercializing the VitaGuard MRD platform in Southeast Asia after a working visit to Tongshu Gene facilities in China.83d ago